<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00513240</url>
  </required_header>
  <id_info>
    <org_study_id>R21HD5550101</org_study_id>
    <secondary_id>FDA IND #100011</secondary_id>
    <secondary_id>Baylor GCRC #0942</secondary_id>
    <nct_id>NCT00513240</nct_id>
  </id_info>
  <brief_title>Erythropoetin Neuroprotection for Neonatal Cardiac Surgery</brief_title>
  <official_title>Erythropoetin Neuroprotection for Neonatal Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Dana Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on
      neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long
      term development problems such as learning disorders and hyperactivity syndromes. This study
      aims to determine if erythropoetin, a natural hormone made in the body, protects the brain
      from damage when given in high doses before and during neonatal open heart surgery. We will
      use brain MRI, brain wave tests (EEG), neurological examination, and long term developmental
      outcome testing to see if erythropoetin is better than salt water injection (placebo) in
      protecting the brain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Erythropoetin (EPO) will protect the neonatal brain in the perioperative period
      for congenital heart surgery.

      Using a prospective, randomized, placebo-controlled, double-blinded design, the specific aims
      of this study are:

        1. To determine the effect of perioperative EPO on short and long term neurological
           outcomes in neonates undergoing cardiac surgery with an optimized cardiopulmonary bypass
           strategy.

        2. To determine EPO tolerability and safety with short term administration.

        3. To determine EPO pharmacokinetics in this population.

        4. To determine the relationship of neurological monitoring, specifically NIRS, to
           neurological outcomes with an optimized cardiopulmonary bypass technique in neonates
           that avoids deep hypothermic circulatory arrest, and to determine if EPO affects this
           relationship.

      Protocol: Neonates undergoing arterial switch, Norwood, or aortic arch advancement/other
      complete 2 ventricle repair, &gt;35 weeks gestation and ≥2.0 kg are eligible.

      Preop day 1:NIRS for 12-24 hours, neuro exam, and Study drug dose #1: EPO 500 units/kg or
      saline placebo 12-72 hours before surgery. EPO Pharmacokinetic data for 25-50 consenting
      patients.

      Day of surgery: Brain MRI immediately preop. Anesthesia/CPB per our standard practice
      (fentanyl 100-200 mcg/kg, midazolam, isoflurane, epsilon-aminocaproic acid, 75 mg/kg IV load
      to patient and CPB prime, and 75 mg/kg/hr infusion in OR) with ACP guided by TCD, pH stat,
      hct 30-35, avoid DHCA.

      POD #1: Study drug dose #2: EPO 500 units/kg or saline placebo 24 hours after dose #2.

      For 72 hours postop, NIRS monitoring. All monitor data collected electronically.

      POD #3: Study drug dose #3: EPO 500 units/kg or saline placebo 48 hours after dose #3.

      7 days postop: Brain MRI. (pentobarbital IV). Neuro exam before discharge. 3-6 months: Brain
      MRI immediately before or after 2nd surgery, or as outpatient (IV pentobarb or
      propofol/midazolam—may use N2O/sevo for induction, cannot intubate if outpatient; OR if
      cardiac MRI at same time, any indicated anesthetic technique). NIRS x 24h after 2nd surgery.

      1,and 3 years: Bayley Scales of Infant Development III. 5 years: Battery of
      neurodevelopmental tests.

      Early primary outcome variable: MRI severity of injury score (decrease by 25%). Late outcome
      variable Bayley Scales of Infant Development score: improvement by 18% at age 1 years.

      Sample size: 60 patients: stratified into 3 groups to give power 0.85, alpha 0.05. Expect to
      accrue 2-4 patients per month.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI Severity of Injury Score</measure>
    <time_frame>7 days postoperatively.</time_frame>
    <description>MRI severity of injury score change from preoperative brain MRI to 7 day postoperative MRI(decrease by 25%). Scoring of infarction, hemorrhage, white matter injury, cerebral venous sinus thrombosis, or increased lactate on MR spectroscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Scores on Bayley Scales of Infant Development III at Age 1 Years.</measure>
    <time_frame>1 year postoperatively</time_frame>
    <description>3 domains of the Bayley Scales of Infant Development III: Cognitive, Language and Motor Minimum score = 45, maximum score = 155; Population mean = 100, SD = 15; Higher scores are indicative of better outcomes Language scores are reflective of receptive communication and expressive communication subscales. Motor scores are reflective of fine motor and gross motor subscales.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EEG Seizure Burden in the First 72 Postoperative Hours. (Total Minutes of EEG Seizures).</measure>
    <time_frame>72 hours postoperatively.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of High Dose Erythropoetin: 7 Erythropoetin Levels in First 24 Hours After First Dose.</measure>
    <time_frame>24 hours after first EPO dose.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Congenital Heart Disease</condition>
  <condition>Hypoplastic Left Heart Syndrome</condition>
  <condition>Transposition of the Great Arteries</condition>
  <condition>Aortic Arch Hypoplasia or Interruption</condition>
  <arm_group>
    <arm_group_label>EPO group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to receive the 3 doses of erythropoetin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group.</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized to receive 3 doses of normal saline control.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoetin</intervention_name>
    <description>Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2</description>
    <arm_group_label>EPO group</arm_group_label>
    <other_name>Procrit</other_name>
    <other_name>Epoetin alpha</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.</description>
    <arm_group_label>Control group.</arm_group_label>
    <other_name>Saline placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates (&lt;30 days) undergoing cardiac surgery with cardiopulmonary bypass will be
             enrolled.

          -  Inclusion criteria include patients with:

               -  single ventricle: hypoplastic left heart syndrome or variant undergoing Norwood
                  Stage I or Sano palliation (SV group);

               -  patients with D-transposition of the great vessels with or without ventricular
                  septal defect (VSD) undergoing arterial switch operation with VSD closure if
                  needed (ASO group); and

               -  patients with interrupted or hypoplastic aortic arch with intracardiac defects
                  (VSD, ASD, or subaortic stenosis) who are undergoing complete 2- ventricle repair
                  including aortic arch advancement(AAA group), any other 2 ventricle lesion
                  scheduled for complex anatomic repair.

        Exclusion Criteria:

          -  Gestational age less than 35 weeks at birth

          -  Weight less than 2 kg

          -  Known recognizable dysmorphic syndrome

          -  Surgery not requiring cardiopulmonary bypass

          -  Preoperative cardiac arrest requiring chest compressions for greater than 3 minutes

          -  Inability to enroll the patient greater than 12 hours preoperatively

          -  Aortic crossclamping is not used

          -  CPB times are anticipated to be less than 60 minutes

          -  A nadir temperature on bypass greater than 25° C is planned.

          -  Presence of known contraindications to EPO administration-sustained systolic blood
             pressure &gt;100, hemoglobin .18 g/dL, known allergy to EPO or one of its components

          -  Platelet count &gt;600,000 per dL, INR &lt;0.8.

          -  Maternal history of major vascular thrombosis, or multiple fetal loss (3 or more
             spontaneous abortions).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>30 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean B. Andropoulos, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine/Texas Children's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://TexasChildrensHospital.org</url>
    <description>Texas Children's Hospital Web Site</description>
  </link>
  <link>
    <url>http://www.bcm.edu</url>
    <description>Baylor College of Medicine Web Site</description>
  </link>
  <link>
    <url>http://www.pedsanesthesia.org/ccas/</url>
    <description>Congenital Cardiac Anesthesia Society Web Page</description>
  </link>
  <link>
    <url>http://www.americanheart.org/children.</url>
    <description>American Heart Association Web Page--Congenital Heart Disease</description>
  </link>
  <link>
    <url>http://www.nichd.nih.gov</url>
    <description>National Institutes of Health: National Institute of Child Health and Developement Web Site</description>
  </link>
  <reference>
    <citation>Kellert BA, McPherson RJ, Juul SE. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res. 2007 Apr;61(4):451-5.</citation>
    <PMID>17515870</PMID>
  </reference>
  <reference>
    <citation>McPherson RJ, Demers EJ, Juul SE. Safety of high-dose recombinant erythropoietin in a neonatal rat model. Neonatology. 2007;91(1):36-43. Epub 2006 Nov 10.</citation>
    <PMID>17344650</PMID>
  </reference>
  <reference>
    <citation>Galli KK, Zimmerman RA, Jarvik GP, Wernovsky G, Kuypers MK, Clancy RR, Montenegro LM, Mahle WT, Newman MF, Saunders AM, Nicolson SC, Spray TL, Gaynor JW. Periventricular leukomalacia is common after neonatal cardiac surgery. J Thorac Cardiovasc Surg. 2004 Mar;127(3):692-704. Erratum in: J Thorac Cardiovasc Surg. 2004 Sep;128(3):498. Galli, Kristen K [corrected to Galli, Kristin K].</citation>
    <PMID>15001897</PMID>
  </reference>
  <reference>
    <citation>Andropoulos DB, Stayer SA, Diaz LK, Ramamoorthy C. Neurological monitoring for congenital heart surgery. Anesth Analg. 2004 Nov;99(5):1365-75; table of contents. Review.</citation>
    <PMID>15502032</PMID>
  </reference>
  <reference>
    <citation>Andropoulos DB, Stayer SA, McKenzie ED, Fraser CD Jr. Regional low-flow perfusion provides comparable blood flow and oxygenation to both cerebral hemispheres during neonatal aortic arch reconstruction. J Thorac Cardiovasc Surg. 2003 Dec;126(6):1712-7.</citation>
    <PMID>14688677</PMID>
  </reference>
  <reference>
    <citation>Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA. 2005 Jan 5;293(1):90-5. Review.</citation>
    <PMID>15632341</PMID>
  </reference>
  <reference>
    <citation>McQuillen PS, Barkovich AJ, Hamrick SE, Perez M, Ward P, Glidden DV, Azakie A, Karl T, Miller SP. Temporal and anatomic risk profile of brain injury with neonatal repair of congenital heart defects. Stroke. 2007 Feb;38(2 Suppl):736-41.</citation>
    <PMID>17261728</PMID>
  </reference>
  <reference>
    <citation>Chang YS, Mu D, Wendland M, Sheldon RA, Vexler ZS, McQuillen PS, Ferriero DM. Erythropoietin improves functional and histological outcome in neonatal stroke. Pediatr Res. 2005 Jul;58(1):106-11. Epub 2005 May 5.</citation>
    <PMID>15879287</PMID>
  </reference>
  <reference>
    <citation>Ballweg JA, Wernovsky G, Gaynor JW. Neurodevelopmental outcomes following congenital heart surgery. Pediatr Cardiol. 2007 Mar-Apr;28(2):126-33. Epub 2007 Jan 29. Review.</citation>
    <PMID>17265108</PMID>
  </reference>
  <reference>
    <citation>Karl TR, Hall S, Ford G, Kelly EA, Brizard CP, Mee RB, Weintraub RG, Cochrane AD, Glidden D. Arterial switch with full-flow cardiopulmonary bypass and limited circulatory arrest: neurodevelopmental outcome. J Thorac Cardiovasc Surg. 2004 Jan;127(1):213-22.</citation>
    <PMID>14752433</PMID>
  </reference>
  <reference>
    <citation>Wypij D, Newburger JW, Rappaport LA, duPlessis AJ, Jonas RA, Wernovsky G, Lin M, Bellinger DC. The effect of duration of deep hypothermic circulatory arrest in infant heart surgery on late neurodevelopment: the Boston Circulatory Arrest Trial. J Thorac Cardiovasc Surg. 2003 Nov;126(5):1397-403.</citation>
    <PMID>14666011</PMID>
  </reference>
  <reference>
    <citation>Zhu C, Kang W, Xu F, Cheng X, Zhang Z, Jia L, Ji L, Guo X, Xiong H, Simbruner G, Blomgren K, Wang X. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009 Aug;124(2):e218-26. doi: 10.1542/peds.2008-3553. Epub 2009 Jul 27.</citation>
    <PMID>19651565</PMID>
  </reference>
  <reference>
    <citation>Andropoulos DB, Mizrahi EM, Hrachovy RA, Stayer SA, Stark AR, Heinle JS, McKenzie ED, Dickerson HA, Meador MR, Fraser CD Jr. Electroencephalographic seizures after neonatal cardiac surgery with high-flow cardiopulmonary bypass. Anesth Analg. 2010 Jun 1;110(6):1680-5. doi: 10.1213/ANE.0b013e3181dd5a58. Epub 2010 Apr 30.</citation>
    <PMID>20435942</PMID>
  </reference>
  <reference>
    <citation>Andropoulos DB, Hunter JV, Nelson DP, Stayer SA, Stark AR, McKenzie ED, Heinle JS, Graves DE, Fraser CD Jr. Brain immaturity is associated with brain injury before and after neonatal cardiac surgery with high-flow bypass and cerebral oxygenation monitoring. J Thorac Cardiovasc Surg. 2010 Mar;139(3):543-56. doi: 10.1016/j.jtcvs.2009.08.022. Epub 2009 Nov 11.</citation>
    <PMID>19909994</PMID>
  </reference>
  <reference>
    <citation>McPherson RJ, Juul SE. Erythropoietin for infants with hypoxic-ischemic encephalopathy. Curr Opin Pediatr. 2010 Apr;22(2):139-45. doi: 10.1097/MOP.0b013e328336eb57. Review.</citation>
    <PMID>20090525</PMID>
  </reference>
  <reference>
    <citation>Juul SE, McPherson RJ, Bauer LA, Ledbetter KJ, Gleason CA, Mayock DE. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics. 2008 Aug;122(2):383-91. doi: 10.1542/peds.2007-2711.</citation>
    <PMID>18676557</PMID>
  </reference>
  <reference>
    <citation>Fauchère JC, Dame C, Vonthein R, Koller B, Arri S, Wolf M, Bucher HU. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics. 2008 Aug;122(2):375-82. doi: 10.1542/peds.2007-2591.</citation>
    <PMID>18676556</PMID>
  </reference>
  <reference>
    <citation>Brown MS, Eichorst D, Lala-Black B, Gonzalez R. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics. 2009 Oct;124(4):e681-7. doi: 10.1542/peds.2008-2701. Epub 2009 Sep 28.</citation>
    <PMID>19786428</PMID>
  </reference>
  <results_reference>
    <citation>Andropoulos DB, Brady K, Easley RB, Dickerson HA, Voigt RG, Shekerdemian LS, Meador MR, Eisenman CA, Hunter JV, Turcich M, Rivera C, McKenzie ED, Heinle JS, Fraser CD Jr. Erythropoietin neuroprotection in neonatal cardiac surgery: a phase I/II safety and efficacy trial. J Thorac Cardiovasc Surg. 2013 Jul;146(1):124-31. doi: 10.1016/j.jtcvs.2012.09.046. Epub 2012 Oct 23.</citation>
    <PMID>23102686</PMID>
  </results_reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2007</study_first_submitted>
  <study_first_submitted_qc>August 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>January 24, 2014</results_first_submitted>
  <results_first_submitted_qc>April 17, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 19, 2014</results_first_posted>
  <last_update_submitted>November 9, 2016</last_update_submitted>
  <last_update_submitted_qc>November 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Dean Andropoulos</investigator_full_name>
    <investigator_title>Professor, Chief of Pediatric Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>erythropoetin</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>neonate</keyword>
  <keyword>cardiac</keyword>
  <keyword>magnetic resonance imaging</keyword>
  <keyword>brain magnetic resonance imaging</keyword>
  <keyword>electroencephalogram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hypoplastic Left Heart Syndrome</mesh_term>
    <mesh_term>Transposition of Great Vessels</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects recruited from September 2006 to February 2011 in the Texas Children's Hospital Heart Center NICU and CVICU.</recruitment_details>
      <pre_assignment_details>357 assessed for eligibility; 253 did not meet inclusion criteria. 42 subjects that eligible but consent not obtained (24 declined, 2 enrolled in another study, 16 investigator not available for consent or patient lived too far away). 62 consented, enrolled, received 1 dose EPO, but intended surgery not done on 3 subjects (no CPB); leaving 59.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>EPO Group</title>
          <description>Patients randomized to receive the 3 doses of erythropoetin.
Erythropoetin: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2</description>
        </group>
        <group group_id="P2">
          <title>Control Group.</title>
          <description>Patients randomized to receive 3 doses of normal saline control.
Normal saline: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35">3 did not have intended surgery; 28 had all 3 doses; 4 had 1 dose but no more due to delayed surgery</participants>
                <participants group_id="P2" count="27">25 had 3 doses; 1 had 1 dose due to rash; 1 had 2 doses and 1 dose of EPO due to pharmacy error</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Clinical Data Collection &amp;Pre/Postop MRI</title>
              <participants_list>
                <participants group_id="P1" count="32">3 not having intended surgery are subtracted from original 35 subjects, leaving 32</participants>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22">Competed 12 month neurodevelopmental exam, which are the only results published at this time.</participants>
                <participants group_id="P2" count="20">Competed 12 month neurodevelopmental exam, which are the only results published at this time.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not have intended surgery</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>These were the number of subjects followed for the intention-to-treat analysis because they received at least one dose of study drug/placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>EPO Group</title>
          <description>Patients randomized to receive the 3 doses of erythropoetin.
Erythropoetin: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2</description>
        </group>
        <group group_id="B2">
          <title>Control Group.</title>
          <description>Patients randomized to receive 3 doses of normal saline control.
Normal saline: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age at inclusion surgery</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.94" spread="5.35"/>
                    <measurement group_id="B2" value="8.12" spread="4.09"/>
                    <measurement group_id="B3" value="8.58" spread="4.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cardiac diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hypoplastic Left Heart Syndrome (HLHS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>(D-Transposition of the Great Arteries (D-TGA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aortic Arch &amp; Ventricular Septal Defect/Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Any preoperative MRI injury</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New postoperative MRI injury</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>MRI Severity of Injury Score</title>
        <description>MRI severity of injury score change from preoperative brain MRI to 7 day postoperative MRI(decrease by 25%). Scoring of infarction, hemorrhage, white matter injury, cerebral venous sinus thrombosis, or increased lactate on MR spectroscopy.</description>
        <time_frame>7 days postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Scores on Bayley Scales of Infant Development III at Age 1 Years.</title>
        <description>3 domains of the Bayley Scales of Infant Development III: Cognitive, Language and Motor Minimum score = 45, maximum score = 155; Population mean = 100, SD = 15; Higher scores are indicative of better outcomes Language scores are reflective of receptive communication and expressive communication subscales. Motor scores are reflective of fine motor and gross motor subscales.</description>
        <time_frame>1 year postoperatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EPO 1000 Units/kg QDx3</title>
            <description>Original dose of 1000 units/kg every day for 3 doses</description>
          </group>
          <group group_id="O2">
            <title>EPO 500 Units/kg QODx3</title>
            <description>Revised dose after FDA clinical hold removed of EPO 500 units/kg every other day for 3 doses</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Scores on Bayley Scales of Infant Development III at Age 1 Years.</title>
          <description>3 domains of the Bayley Scales of Infant Development III: Cognitive, Language and Motor Minimum score = 45, maximum score = 155; Population mean = 100, SD = 15; Higher scores are indicative of better outcomes Language scores are reflective of receptive communication and expressive communication subscales. Motor scores are reflective of fine motor and gross motor subscales.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12-Month BSID-III Cognitive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101.4" spread="16.9"/>
                    <measurement group_id="O2" value="100.9" spread="10.2"/>
                    <measurement group_id="O3" value="106.3" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Month BSID-III Language</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" spread="16.3"/>
                    <measurement group_id="O2" value="92.0" spread="7.3"/>
                    <measurement group_id="O3" value="92.4" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-Month BSID-III Motor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3" spread="15.7"/>
                    <measurement group_id="O2" value="90.5" spread="8.6"/>
                    <measurement group_id="O3" value="92.6" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EEG Seizure Burden in the First 72 Postoperative Hours. (Total Minutes of EEG Seizures).</title>
        <time_frame>72 hours postoperatively.</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of High Dose Erythropoetin: 7 Erythropoetin Levels in First 24 Hours After First Dose.</title>
        <time_frame>24 hours after first EPO dose.</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>EPO Group</title>
          <description>Patients randomized to receive the 3 doses of erythropoetin.
Erythropoetin: Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2</description>
        </group>
        <group group_id="E2">
          <title>Control Group.</title>
          <description>Patients randomized to receive 3 doses of normal saline control.
Normal saline: Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Postop ECMO</sub_title>
                <description>Cardiac arrest and subsequent ECMO</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative dural sinovenous thrombosis</sub_title>
                <description>As evidenced by MRI exam</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Clinical seizures</sub_title>
                <description>Clinical seizures diagnosed by physician exam</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>New cerebral infarction adjuacent to thrombosis on postop MRI</sub_title>
                <description>New cerebral infarction adjuacent to thrombosis on postop MRI</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dean B. Andropoulos</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-826-5831</phone>
      <email>dra@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

